Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ: PLRX )

3.040 -0.250 (-7.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings for Pliant Therapeutics
Via Benzinga
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
The company has a potentially best-in-class approach to a lung condition. 
Via Investor's Business Daily
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The... 
Via Benzinga
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its... 
Via Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500... 
Via Benzinga
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday. 
Via Benzinga
Why Is Xylem (XYL) Stock Down 9% Today
Xylem (XYL) stock is slipping on Monday after the company revealed plans to acquire Evoqua (AQUA) in a $7.5 billion deal. 
Via InvestorPlace
Why Is Ryvyl (RVYL) Stock Is On the Move Today?
Ryvyl (RVYL) stock is on the move Monday after saying its prior financial data can no longer be relied on and revealing an investigation. 
Via InvestorPlace
Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know
What's trending on Social Media today: 
Via Benzinga
Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today?
Pliant Therapeutics (PLRX) stock is taking off on Monday after releasing positive Phase 2a clinical trial data for bexotegrast. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday! 
Via InvestorPlace
Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder
Pliant Therapeutics Inc (NASDAQ: PLRX) has announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic... 
Via Benzinga
Salesforce, Tesla And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
These drugmakers have bucked the overall market's downward trend this year and expectations are still high. 
Via The Motley Fool
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
From Pliant Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.